Skip to main content

Tetanus

20
Pipeline Programs
8
Companies
37
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
5
0
12
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
15100%
+ 28 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

MCM Vaccines
MCM VaccinesNetherlands - Leiden
1 program
1
Td5apPhase 41 trial
Active Trials
NCT00870350Unknown400Est. Jun 2010
ViiV Healthcare
ViiV HealthcareNC - Durham
15 programs
5
10
BoostrixPhase 3
BoostrixPhase 3
Boostrix®Phase 3
DTPa-IPVPhase 3
GSK Biologicals'Kinrix®Phase 3
+10 more programs
CanSino Biologics
CanSino BiologicsChina - Tianjin
2 programs
1
1
TTVAPhase 31 trial
TTVAPhase 11 trial
Active Trials
NCT06123663Completed60Est. Jun 2024
NCT06120751Completed1,000Est. Sep 2024
Sinovac Biotech
Sinovac BiotechChina - Beijing
2 programs
1
1
Investigational tetanus vaccine, adsorbedPhase 3Vaccine1 trial
SNA02-48Phase 1/21 trial
Active Trials
NCT06939777Not Yet Recruiting255Est. Feb 2026
NCT06049940Completed1,260Est. Mar 2024
GSK
GSKLONDON, United Kingdom
15 programs
GSK2202083A vaccinePHASE_2Vaccine1 trial
GSK2202083A vaccinePHASE_2Vaccine1 trial
GSK2202083A vaccinePHASE_2Vaccine1 trial
GSK2202083A vaccinePHASE_2Vaccine1 trial
Infanrix hexa™PHASE_21 trial
+10 more programs
Active Trials
NCT00871741Terminated16Est. Jun 2009
NCT00970307Completed421Est. Jan 2010
NCT01090453Completed480Est. Oct 2011
+12 more trials
Sanofi
SanofiPARIS, France
5 programs
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1PHASE_1_2Vaccine1 trial
TdapPHASE_35 trials
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis AdsorbedPHASE_41 trial
Tetanus Toxoid, Diphtheria Toxoid and Pertussis VaccinePHASE_4Vaccine1 trial
Tetanus-diphtheria-acellular pertussisPHASE_41 trial
Active Trials
NCT02587520Completed1,363Est. Feb 2017
NCT06258057Active Not Recruiting365,000Est. Dec 2026
NCT05264662Active Not Recruiting511Est. Jun 2025
+6 more trials
GC Biopharma
GC BiopharmaKorea - Yongin
2 programs
Biological: GC3111 vaccinePHASE_1_2Vaccine1 trial
GC3111 vaccinePHASE_2Vaccine1 trial
Active Trials
NCT02813486Unknown220Est. Nov 2016
NCT04238975Unknown213Est. May 2021
Grifols
GrifolsNEW YORK, NY
1 program
Tetanus Immune GlobulinPHASE_41 trial
Active Trials
NCT00437671Terminated6Est. Sep 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiTdap
SanofiTdap
SanofiTetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine
SanofiAdacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
MCM VaccinesTd5ap
GrifolsTetanus Immune Globulin
SanofiTetanus-diphtheria-acellular pertussis
CanSino BiologicsTTVA
Sinovac BiotechInvestigational tetanus vaccine, adsorbed
SanofiTdap
SanofiTdap
GSKBoostrix
GSKInfanrix-IPV/Hib™
SanofiTdap
GSKGSK Biologicals'Kinrix®

Showing 15 of 37 trials with date data

Clinical Trials (37)

Total enrollment: 388,416 patients across 37 trials

Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women

Start: Mar 2022Est. completion: Jun 2025511 patients
Phase 4Active Not Recruiting

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

Start: Jan 2021Est. completion: Jan 2023273 patients
Phase 4Completed
NCT01439165SanofiTetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Start: Nov 2011Est. completion: Feb 20171,330 patients
Phase 4Completed
NCT01311557SanofiAdacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

Start: Mar 2011Est. completion: Jan 20121,302 patients
Phase 4Completed

An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster

Start: Apr 2009Est. completion: Jun 2010400 patients
Phase 4Unknown
NCT00437671GrifolsTetanus Immune Globulin

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Start: Mar 2007Est. completion: Sep 20076 patients
Phase 4Terminated
NCT00347958SanofiTetanus-diphtheria-acellular pertussis

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

Start: Aug 2006Est. completion: Oct 2008545 patients
Phase 4Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Start: Mar 2024Est. completion: Sep 20241,000 patients
Phase 3Completed
NCT06049940Sinovac BiotechInvestigational tetanus vaccine, adsorbed

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Start: Sep 2023Est. completion: Mar 20241,260 patients
Phase 3Completed

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

Start: Mar 2014Est. completion: Mar 2015534 patients
Phase 3Completed

Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.

Start: Nov 2013Est. completion: Apr 20151,440 patients
Phase 3Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

Start: Jan 2013Est. completion: Apr 2014165 patients
Phase 3Completed
NCT01086423GSKInfanrix-IPV/Hib™

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Start: Mar 2010Est. completion: Nov 2010985 patients
Phase 3Completed

Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults

Start: Jul 2009Est. completion: Dec 200952 patients
Phase 3Completed
NCT00871117GSKGSK Biologicals'Kinrix®

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Start: Mar 2009Est. completion: Jun 2010478 patients
Phase 3Completed
NCT00835237GSKBoostrix®

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Start: Feb 2009Est. completion: Oct 20091,332 patients
Phase 3Completed

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

Start: Apr 2007Est. completion: Dec 20091,045 patients
Phase 3Completed
NCT00412854GSKInfanrix™/Hib

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Start: Jan 2007Est. completion: Jun 2007660 patients
Phase 3Completed

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

Start: Jan 2007Est. completion: Feb 200730 patients
Phase 3Completed
NCT00379977GSKdiphtheria, tetanus, pertussis & Hib vaccine

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

Start: Sep 2006Est. completion: Dec 200630 patients
Phase 3Completed
NCT00197275GSKHib-MenAC mixed with Tritanrix™-HepB

Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Start: Feb 2006Est. completion: Nov 2006800 patients
Phase 3Completed

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Start: Jan 2006Est. completion: Jan 2007458 patients
Phase 3Completed
NCT00148941GSKSB213503 lot 1

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Start: Jan 2005Est. completion: Dec 20064,209 patients
Phase 3Completed

Pertussis Maternal Immunization Study

Start: Nov 2007Est. completion: Dec 2015320 patients
Phase 2/3Completed

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Start: Oct 2019Est. completion: May 2021213 patients
Phase 2Unknown
NCT01248884GSKInfanrix hexa™

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Start: Dec 2010Est. completion: Jan 2012721 patients
Phase 2Completed
NCT01171989GSKGSK2202083A vaccine

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Start: Aug 2010Est. completion: Dec 2010391 patients
Phase 2Completed
NCT01090453GSKGSK2202083A vaccine

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Start: May 2010Est. completion: Oct 2011480 patients
Phase 2Completed
NCT00970307GSKGSK2202083A vaccine

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Start: Aug 2009Est. completion: Jan 2010421 patients
Phase 2Completed
NCT00871741GSKGSK2202083A vaccine

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Start: Apr 2009Est. completion: Jun 200916 patients
Phase 2Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

Start: Apr 2025Est. completion: Feb 2026255 patients
Phase 1/2Not Yet Recruiting
NCT02813486GC BiopharmaBiological: GC3111 vaccine

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

Start: Jun 2016Est. completion: Nov 2016220 patients
Phase 1/2Unknown
NCT02587520SanofiTetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

Start: Oct 2015Est. completion: Feb 20171,363 patients
Phase 1/2Completed

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Start: Dec 2023Est. completion: Jun 202460 patients
Phase 1Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Start: Jun 2019Est. completion: Apr 202171 patients
Phase 1Completed

Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China

Start: Aug 2013Est. completion: Jan 201440 patients
Phase 1Completed

Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy

Start: Jan 2024Est. completion: Dec 2026365,000 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.